268 related articles for article (PubMed ID: 18563177)
1. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses.
Mouquet H; Musette P; Gougeon ML; Jacquot S; Lemercier B; Lim A; Gilbert D; Dutot I; Roujeau JC; D'Incan M; Bedane C; Tron F; Joly P
J Invest Dermatol; 2008 Dec; 128(12):2859-69. PubMed ID: 18563177
[TBL] [Abstract][Full Text] [Related]
2. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion.
Zambruno G; Borradori L
J Invest Dermatol; 2008 Dec; 128(12):2745-7. PubMed ID: 18997839
[TBL] [Abstract][Full Text] [Related]
3. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris.
Nagel A; Podstawa E; Eickmann M; Müller HH; Hertl M; Eming R
J Invest Dermatol; 2009 Sep; 129(9):2202-10. PubMed ID: 19282839
[TBL] [Abstract][Full Text] [Related]
4. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.
Colliou N; Picard D; Caillot F; Calbo S; Le Corre S; Lim A; Lemercier B; Le Mauff B; Maho-Vaillant M; Jacquot S; Bedane C; Bernard P; Caux F; Prost C; Delaporte E; Doutre MS; Dreno B; Franck N; Ingen-Housz-Oro S; Chosidow O; Pauwels C; Picard C; Roujeau JC; Sigal M; Tancrede-Bohin E; Templier I; Eming R; Hertl M; D'Incan M; Joly P; Musette P
Sci Transl Med; 2013 Mar; 5(175):175ra30. PubMed ID: 23467561
[TBL] [Abstract][Full Text] [Related]
5. Rituximab exerts a dual effect in pemphigus vulgaris.
Eming R; Nagel A; Wolff-Franke S; Podstawa E; Debus D; Hertl M
J Invest Dermatol; 2008 Dec; 128(12):2850-8. PubMed ID: 18563178
[TBL] [Abstract][Full Text] [Related]
6. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
7. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
Feldman RJ; Christen WG; Ahmed AR
Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
[TBL] [Abstract][Full Text] [Related]
8. Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen.
Hébert V; Petit M; Maho-Vaillant M; Golinski ML; Riou G; Derambure C; Boyer O; Joly P; Calbo S
Front Immunol; 2019; 10():1794. PubMed ID: 31440235
[TBL] [Abstract][Full Text] [Related]
9. Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus.
Maho-Vaillant M; Perals C; Golinski ML; Hébert V; Caillot F; Mignard C; Riou G; Petit M; Viguier M; Hertl M; Boyer O; Calbo S; Fazilleau N; Joly P
J Invest Dermatol; 2021 Sep; 141(9):2132-2140.e1. PubMed ID: 33766510
[TBL] [Abstract][Full Text] [Related]
10. Pemphigus: Current and Future Therapeutic Strategies.
Didona D; Maglie R; Eming R; Hertl M
Front Immunol; 2019; 10():1418. PubMed ID: 31293582
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
[TBL] [Abstract][Full Text] [Related]
12. Impaired function of CD19(+) CD24(hi) CD38(hi) regulatory B cells in patients with pemphigus.
Zhu HQ; Xu RC; Chen YY; Yuan HJ; Cao H; Zhao XQ; Zheng J; Wang Y; Pan M
Br J Dermatol; 2015 Jan; 172(1):101-10. PubMed ID: 24935080
[TBL] [Abstract][Full Text] [Related]
13. Why rituximab works.
Tzu J; Kim N; Kirsner RS
J Invest Dermatol; 2008 Dec; 128(12):2744. PubMed ID: 18997838
[No Abstract] [Full Text] [Related]
14. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.
Feldman RJ; Ahmed AR
Expert Rev Clin Immunol; 2011 Jul; 7(4):529-41. PubMed ID: 21790294
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
16. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
Arin MJ; Engert A; Krieg T; Hunzelmann N
Br J Dermatol; 2005 Sep; 153(3):620-5. PubMed ID: 16120153
[TBL] [Abstract][Full Text] [Related]
18. Rituximab as monotherapy for elicited xenoreactive antibody responses.
Gonzalez-Stawinski GV; Davis RD
J Heart Lung Transplant; 2006 Dec; 25(12):1462-6. PubMed ID: 17178342
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.
Hassan R; Williams-Gould J; Watson T; Pai-Scherf L; Pastan I
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):16-8. PubMed ID: 14734446
[TBL] [Abstract][Full Text] [Related]
20. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
